Corvus Pharmaceuticals, Inc. (CRVS)

Market Cap	38.17M
Revenue (ttm)	n/a
Net Income (ttm)	-40.73M
Shares Out	46.55M
EPS (ttm)	-0.87
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	121,829
Open	0.820
Previous Close	0.825
Day's Range	0.810 - 0.866
52-Week Range	0.695 - 2.170
Beta	1.01
Analysts	Buy
Price Target	2.89 (+252.48%)
Earnings Date	Mar 9, 2023

About CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 23, 2016
• Employees: 28
• Stock Exchange: NASDAQ
• Ticker Symbol: CRVS

Analyst Forecast

According to 9 analysts, the average rating for CRVS stock is "Buy." The 12-month stock price forecast is $2.89, which is an increase of 252.48% from the latest price.

Price Target

$2.89

(252.48% upside)

Analyst Consensus: Buy